Translating EU presence to US market successCompanies looking to replicate a drug’s EU market success in the US will face significant hurdles unless they Share XTranslating EU presence to US market successhttps://deep-dive.pharmaphorum.com/magazine/communications-and-commercialisation/eu-us-pharma-market-success/
Incyte, MorphoSys’ CAR-T rival tafasitamab approved in EUIncyte and MorphoSys’ antibody therapy tafasitamab has been approved in Europe, promising to provide a more convenient alternative Share XIncyte, MorphoSys’ CAR-T rival tafasitamab approved in EUhttps://pharmaphorum.com/news/incyte-morphosys-car-t-rival-tafasitamab-approved-in-eu/
AbbVie’s Rinvoq cleared in EU for atopic dermatitisThe FDA may be reluctant to trust JAK inhibitors, but the European Commission is more willing, and has Share XAbbVie’s Rinvoq cleared in EU for atopic dermatitishttps://pharmaphorum.com/news/abbvies-rinvoq-is-first-jak-drug-cleared-in-eu-for-atopic-dermatitis/
IL-17 tailender UCB gets EU OK for bimekizumab in psoriasisUCB has been bringing up the rear in the IL-17 inhibitor category with bimekizumab, but now has EU Share XIL-17 tailender UCB gets EU OK for bimekizumab in psoriasishttps://pharmaphorum.com/news/il-17-tailender-ucb-gets-eu-ok-for-bimekizumab-in-psoriasis/
After FDA snub, EMA backs FibroGen, Astellas’ roxadustatThe EU regulator has approved FibroGen and Astellas Evrenzo for adults with anaemia caused by chronic kidney disease Share XAfter FDA snub, EMA backs FibroGen, Astellas’ roxadustathttps://pharmaphorum.com/news/after-fda-snub-ema-backs-fibrogen-astellas-roxadustat/
AZ gets European approvals for Forxiga in chronic kidney diseaseAstraZeneca’s Forxiga has become the first SGLT2 inhibitor to be approved in Europe for use in people with Share XAZ gets European approvals for Forxiga in chronic kidney diseasehttps://pharmaphorum.com/news/az-gets-european-approvals-for-forxiga-in-chronic-kidney-disease/
BMS claims first EU okay for adjuvant oesophageal cancer immunotherapyBristol-Myers Squibb is in a battle with Merck & Co for position in the upper gastrointestinal cancer immunotherapy Share XBMS claims first EU okay for adjuvant oesophageal cancer immunotherapyhttps://pharmaphorum.com/news/bms-claims-eu-okay-for-opdivo-in-adjuvant-oesophageal-cancer/
Bluebird claims EU nod for rare disease therapy SkysonaBluebird bio has its first approval for Skysona (formerly Lenti-D), its gene therapy for children with the rare Share XBluebird claims EU nod for rare disease therapy Skysonahttps://pharmaphorum.com/news/bluebird-claims-eu-nod-for-rare-disease-therapy-skysona/
EMA starts review of latecomer GSK/Sanofi COVID-19 vaccineThe EMA has kicked off a rolling review of a COVID-19 vaccine from Sanofi and GlaxoSmithKline, which started Share XEMA starts review of latecomer GSK/Sanofi COVID-19 vaccinehttps://pharmaphorum.com/news/ema-starts-review-of-latecomer-gsk-sanofi-covid-19-vaccine/
